UK Antimicrobial Registry Study - England/Wales/NI
Research type
Research Study
Full title
UK Antimicrobial Registry Study
IRAS ID
323055
Contact name
Gareth Jones
Contact email
Sponsor organisation
University of Aberdeen
Duration of Study in the UK
3 years, 10 months, 1 days
Research summary
Effective antimicrobial agents are a crucial component of modern medicine allowing the elimination or inhibition of growth of microorganisms, including bacteria, viruses, protozoa and fungi. However, microorganisms can develop resistance to antimicrobial agents, decreasing their effectiveness. According to the World Health Organisation, antimicrobial resistance is increasing world-wide, compromising our ability to treat infections, and undermining many other advances in health and medicine. Effective antimicrobial stewardship is key in the fight against antimicrobial resistance, a key element of which is the surveillance of antimicrobial usage, and of antimicrobial resistance.
Understanding usage of antimicrobials in routine clinical settings is important. Randomised trials that lead to the licensing of new agents are commonly conducted in highly select patient populations, often in specialist centres. This may limit the generalisability of trial findings because trial populations fail to capture the clinical variability in the ‘real-world’ patient populations that they ostensibly represent. Estimates of safety, efficacy and cost-effectiveness that arise from these trials may be compromised as a result.
Funded by the British Society for Antimicrobial Chemotherapy (BSAC) the UKAR Study aims to ascertain the usage of recently licensed antimicrobial agents in routine clinical settings. Using this real-world data, we aim to determine how these antimicrobials are currently being utilised, and the outcomes that are achieved. This study will also be uniquely positioned to help identify areas unmet need and inform on antimicrobial stewardship to contribute to the more judicious use of these medicines.REC name
London - Harrow Research Ethics Committee
REC reference
23/LO/0018
Date of REC Opinion
20 Feb 2023
REC opinion
Further Information Favourable Opinion